Antiepileptic potential of *Bacopa monnieri* in the rat brain during PTZ-induced epilepsy with reference to cholinergic system and ATPases

E. Komali, Ch Venkataramaiah, W. Rajendra

Division of Molecular Biology, Department of Zoology, Sri Venkateswara University, Tirupati, 517502, AP, India

**A R T I C L E   I N F O**

Article history:
Received 13 December 2017
Received in revised form 12 May 2019
Accepted 27 February 2020
Available online 4 March 2020

Keywords:
Epilepsy
Pentylenetetrazole
*Bacopa monnieri*
ACh & AChE
ATPases

**A B S T R A C T**

Epilepsy is a chronic central nervous system disorder that occurs not only with the imbalance of glutamatergic neurons and inhibitory gamma-aminobutyric acid (γ-GABA) neurons, but also with abnormal Central cholinergic neuronal regulation. Since long term usage of antiepileptic drugs cause high incidence of pharmacoresistance and untoward side effects, attention has been paid in recent years to screen bioactive compounds from natural medicinal plants for the treatment of several neurological disorders including Epilepsy. Keeping in view of relative importance of natural medicinal plants, the present study is designed to assess the neurotoxicity of Pentylene tetrazole (PTZ), an epileptic compound with particular reference to Cholinergic system and ATPases in different brain regions of rat to explore the possible antiepileptic effect of different extracts of BM in comparison with Diazepam (DZ) (Reference control). The activity levels of Acetyl cholinesterase (AChE) and ATPases were decreased in different regions of brain during PTZ induced epilepsy which were increased in epileptic rats pretreated with different extracts of *Bacopa monnieri* except EAE and AE. In addition Acetylcholine (ACH), levels were increased during PTZ induced epilepsy when compared with normal control and levels were reversed on pretreatment with different extracts of BM. Recoveries of these parameters suggest that the bioactive factors present in the extracts offer neuroprotection by interrupting the pathological cascade that occurs during epileptogenesis.

**1. Introduction**

Epilepsy is one of the most complex groups of neurological disorders resulting in hyper excitability with asymmetrical bursts of electrical activity in different regions of central nervous system. It has been well documented that inhibition of GABAergic activity and/or exaggerated activity of glutamatergic neurotransmission has been primarily implicated in various types of epilepsies. Although a direct role of Cholinergic pathway has not been established, studies in several models of epilepsy have suggested a link between Cholinergic activation and epileptogenesis. In addition it has been recognized that purinergic transmission has also been involved in the release of ATP, as a co transmitter along with glutamate noradrenaline, GABA, acetylcholine and dopamine in the CNS. Accumulating evidence suggest that ATPases such as Na⁺, K⁺ - ATPases Mg²⁺ - ATPase and Ca²⁺ - ATPase play a pivotal role in maintenance of ionic gradient coupled with ATP hydrolysis and modulation of the activities of these enzymes have been associated with epileptogenesis. Considering the multiaxial neurochemical malfunctions as a consequence of epileptic seizures, attempts have been made to design novel antiepileptic drugs (AEDs) targeting different neurotransmitter mechanisms in order to ameliorate the neurological deficits that occur during epileptogenesis. However, clinical management of epilepsy is a very complex task because of co-existing neuro psychiatric complications and manifestation of idiosyncratic reactions.

During the fast few years, focus on ethnopharmacology research has increased all over the world and a growing body of evidence has indicated immense potential of medicinal plants as alternative and
complementary therapies for many human ailments. Bacopa monnieri (BM) is being used in traditional medicine in the treatment of several neurological disorders including epilepsy.11 Bacopa monnieri (brahmi), a traditional ayurvedic medicine has been used for centuries as a memory enhancer, anti-inflammatory, analgesic, antipyretic, and anti-epileptic agent.13 More recently, preclinical studies have reported cognitive enhancing effects with various extracts of Bacopa monnieri. The triterpenoid saponins and their bacosides are responsible for enhancement of nerve impulse activities.10 Keeping in view the neuroprotective role of this medicinal plant the present investigation is carried out to investigate the antiepileptic effect of this medicinal plant during PTZ-induced epilepsy with respect to cholinergic neurotransmission and ATPase activities.

2. Material and methods

2.1. Plant material and preparation of extract

Bacopa Monnieri (BM) plant was collected from Thalakona forest and identified by a botanist, Department of Botany, S.V. University, Tirupati. A voucher specimen was deposited in the herbarium of the Department of Botany, S.V. University, Tirupati (Voucher no. 428). The whole plant was shade dried and reduced to coarse powder. The extraction was carried out as specified by Watoow Phrompitraya et al.(2007).20 The whole plant powder was soaked in ethanol for 2 days at room temperature and the solvent was filtered. This was repeated 3–4 times until the extract gave no coloration. The extract was distilled and concentrated under reduced pressure in the Hahn vapor Rotary Evaporator HS-2005V yielding a gum-like residue, which was then suspended in water and extracted with various organic solvents of increasing polarity (starting with the lipophilic solvent n-Hexane, ending with the more hydrophilic n-Butanol). The solvent from each extract was distilled and concentrated under reduced pressure in the Hahn vapor Rotary Evaporator. The individual extracts were freeze dried and used for further use.

2.2. Animals

Male adult wistar rats weighing 150 ± 25 g were divided into six groups of six animals each and used as the experimental animals in the present investigation. The rats were purchased from the Sri Venkateswara Traders Pvt. Limited, Bangalore, maintained in the animal house of the department in polypropylene cages under laboratory conditions of 28 ± 2 °C temperature with photoperiod of 12 h light and 12 h dark and 75% relative humidity. The rats were maintained according to the ethical guidelines for animal protection and welfare bearing the CPCSEA CPCSCA/IAEC/08 guidelines for animal protection and welfare bearing the CPCSEA CPCSCA/IAEC/08/09/SVU/ZOOL/WR-EK/dt.27.09.2009.

2.3. Drugs and dosing schedule

Pentylentetrazole (PTZ), an anticonvulsant drug, was selected for the present study. It was obtained as commercial grade chemical from Sigma Chemicals, USA. All other chemicals were of analytical grade. Each fraction of BM extract (180 mg/kg body weight) was dissolved in water and given to the animals for one week prior to the injection of PTZ. A gavage tube was used to deliver the substance by the oral route, which is the clinically expected route of administration of BM. The volume of administration was kept at 1 ml to the animal.

2.4. Induction of epilepsy

Convulsions were induced by an intraperitoneal (i.p.) injection of Pentylentetrazole (60 mg/kg body weight) dissolved in saline.21,22

2.5. Administration of the test and reference substance

Each fraction of BM extract (180 mg/kg body weight) was dissolved in water and given to the animals for one week prior to the injection of PTZ.23 Each animal were administered with standard drug diazepam (4 mg/kg, i.p) for one week prior to the injection of PTZ.24

2.6. Isolation of tissues

The animals were sacrificed after the treatment by cervical dislocation. The brain was isolated immediately and placed on a chilled glass plate. Different brain areas viz. cerebral cortex (CC), cerebellum (CB), pons medulla (PM), and hippocampus (HC) were isolated and frozen in liquid nitrogen (−180 °C) and stored at −40 °C until further use. At the time of analyses the tissues were thawed and used for analysis.

2.7. Biochemical analyses

2.7.1. Estimation of acetyl cholinesterase (AchE) activity

Acetyl cholinesterase activity was assayed by the method of Ellmann et al. (1961) with slight modifications.25 The reaction mixture contains 270 μ moles of sodium phosphate buffer (pH 8.0), 10 μ moles of DTNB, 1.5 μ of acetyl thiocholine iodide (AtChI) and 100 μ of 2% brain homogenate. The initial absorbance of the reaction mixture was recorded at 412 nm in a Hitachi U-2000 spectrophotometer prior to the addition of the substrate. The reaction was initiated by adding acetyl thiocholineiodide. After 15 min incubation at room temperature, the yellow colour developed was read at 412 nm. A molar extinction coefficient of 4.12 × 10⁻³ was used to calculate the enzyme activity. The true cholinesterase activity was estimated by running parallel sets with a cholinesterase inhibitor 1:5-bis-[N-allyl-N-methyl-4-aminophenyl] pental-3-one dibromide (BW 284 C51 dibromide). This strongly inhibits the acetylcholinesterase present in the reaction mixture. The pseudo-cholinesterase activity can be calculated from this set. The pseudocholinesterase activity was subtracted from total cholinesterase activity to get true cholinesterase activity. The enzyme activity was expressed as μ moles of acetyl thiocholine hydrolyzed/mg protein/hr.

2.7.2. Acetylcholine (Ach) content

Acetylcholine content was estimated by the method of Hestrin (1949)26 as given by Augustinsson (1957).27 Each region of brain tissue was placed in a test tube and boiled in hot water-bath for 10 min to denature the AChE activity. The tissues were homogenized in 2.0 ml of distilled water. To the homogenate, 1.0 ml of alkaline hydroxylamine hydrochloride was added followed by 1.0 ml of 1.1 hydrochloric acid solution. The contents were mixed thoroughly and centrifuged. To the supernatant 0.5 ml of 0.37 M ferric chloride was added and the brown colour developed was read at 540 nm against the reagent blank. The acetylcholine content was expressed as μ moles of acetylcholine/gm wet weight of tissue.
2.7.3. ATPases (ATP phosphohydrolase)

(a) Mg\(^{2+}\) and Na\(^{+}\), K\(^{+}\) - ATPase activities were assayed by the method of Fritz and Hamrick (1966) as reported by Desai and Ho (1979) with slight modifications.\(^{28}\)

Tissue homogenates were prepared in ice cold 0.32 M sucrose containing 1.0 mM EDTA and 10 mM imidazole (pH 7.5). The homogenates were centrifuged at 1000×g and the supernatant obtained was used as an enzyme source. The reaction mixture in a volume of 3.0 ml contained 3 mM ATP, 3 mM MgCl\(_2\), 100 mM NaCl, 20 mM KCl, 135 mM imidazole hydrochloric acid buffer (pH 7.5) and 10 mg of protein. The reaction mixture was incubated at 37 °C for 30 min and stopped by the addition of 0.1 ml of 50% TCA. Samples were then assayed for inorganic phosphate using the method of Lowry and Lopez (1946) as modified by Phillips and Hayes (1977).\(^{29,30}\) The colour was read at 800 nm in a spectrophotometer. Mg\(^{2+}\) - ATPase activity was measured in presence of 1 mM ouabain, a specific inhibitor of Na\(^{+}\), K\(^{-}\) - ATPase (McIlwain, 1963). Ouabain sensitive Na\(^{+}\), K\(^{-}\) - ATPase activity was obtained by the difference between total ATPase and Mg\(^{2+}\) - ATPase activity. The enzyme activity was expressed as μ moles of inorganic phosphate formed/mg protein/hr.

(b) Ca\(^{2+}\) - ATPase activity was determined by measuring the inorganic phosphate liberated during the hydrolysis of ATP. The reaction mixture contained 135 mM imidazole — HCl buffer (pH 7.5), 5 mM MgCl\(_2\), 0.05 mM CaCl\(_2\), 4 mM ATP and 30 mg of protein. The mixture was incubated at 37 °C for 30 min and stopped by the addition of 0.1 ml of 50% TCA. The inorganic phosphate formed was estimated by the method of Lowry and Lopez (1946) as modified by Phillips and Hayes (1977).\(^{29,30}\) Mg\(^{2+}\) - ATPase activity was measured in the presence of 0.5 mM EGTA and this value was subtracted from total ATPase activity to get Ca\(^{2+}\) - ATPase activity. Enzyme activity was expressed as μ moles of inorganic phosphate formed/mg protein/hr.

2.8. Statistical analysis

The data were expressed as mean, standard deviation (SD) and the normal distributed data were subjected to Analyses of Variance (ANOVA) followed by Dunnett test. P Values < 0.05 were considered significant.

3. Result

ACh content and AChE activity were studied in different brain regions of rat during PTZ-induced epilepsy and on pre-treatment with different extracts of Bacopa monnieri. The ACh content was increased and the AChE activity was decreased during PTZ induced epilepsy in all the areas of brain (CC, CB, HC and PM) when compared to saline control. On pre-treatment with different extracts of Bacopa monnieri, the ACh content and AChE activity recorded maximal recovery in nHE, CE, nBE and EAE treated rats when compared to the PTZ-induced epileptic group (Tables 1 and 2).

The activity levels of Na\(^{+}/K^{+}\) - ATPase, Mg\(^{2+}\) - ATPase and Ca\(^{2+}\) - ATPase were estimated in different areas of the brain during PTZ-induced epilepsy and during the anticonvulsant treatment. The three ATPases recorded decreased activity levels in different regions of rat brain upon administration of PTZ when compared to saline controls. The activity levels were increased in all the brain regions of epileptic rats pre-treated with different extracts of Bacopa monnieri except for the treatment with aqueous extract (AE) when compared to the respective PTZ-induced epileptic group (Tables 3–5).

4. Discussion

Studies on several models of epilepsy have suggested a direct link between cholinergic activation in the hippocampus of mice and epileptogenesis.\(^{1}\) In support of this Turski et al. (1989) reported induction of generalized seizures using muscarinic acetylcholine receptor (mAChR) agonist Pilocarpine.\(^{2}\) The present study demonstrates differential levels of ACh content and AChE activity in different areas of the rat brain. AChE is an enzyme that terminates the signal transmission at the cholinergic synapses of neurons by rapid hydrolysis of the neurotransmitter Ach. Generally brain has the highest AChE activity than the other tissues. The different areas of brain are known to subserve different functions and any change in the cholinergic system of these areas will reflect in the behavior. The present study manifests differential level of ACh content and AChE activity in different areas of the rat brain during induced epilepsy and anti-epileptic treatment. AChE is an enzyme that terminates the signal transmission at the cholinergic synapses of neurons by rapid hydrolysis of the neurotransmitter Ach. Generally brain has the highest AChE activity than the other tissues. The different areas of brain are known to subserve different functions and any change in the cholinergic system of these areas will reflect in the behavior.

The medicinal importance of Brahmi with particular reference to neuroprotection in epilepsy and insomnia has been well documented in Indian traditional literature such as Athar-ved, Charak Samhita, Susrutha Samhita.\(^{3}\) It has also been reported that the extracts of BM improve the activities of antioxidant defense enzymes such as superoxide dismutase (SOD), Catalase (CAT)\(^{4}\) and scavange the free radicals.\(^{5}\) Although the exact mechanism of action of BM is not known, there is evidence that the neuroprotective action could be attributed to a combination of cholinergic modulation and antioxidant effects.

In contrast, the increased AChE and decreased ACh with some plant extracts in all the areas of the brain implicate anticonvulsant effect of Bacopa monnieri extracts. From these result it is obvious that selected extracts of Bacopa monnieri exhibited conspicuous effects on the recovery of PTZ-induced seizures. This indicates that the antiepileptic effect of Bacopa monnieri extracts proceeds through generalized changes in different areas of brain in addition to the specific impact on the target areas. The subsequent decrease and increase in the activities of enzymes in PTZ, and epileptic-treated rats, however, would tend to indicate that direct relationship exists with respect to activities of cholinergic pathway and seizure susceptibility.\(^{11}\) Hence, the changes in the expression of key cholinergic proteins and the associated cholinergic dysfunction may be considered as the key factors in explaining the basic mechanisms underlying in the CNS related epilepsy.\(^{12}\)

Although the direct role of cholinergic pathways during induced epilepsy and antiepileptic treatment has not been demonstrated, these results implicate a mechanism involving a summation of
All the values are Mean, ±SD of six individual observations. Values with same Superscript are significant at P < 0.05. Values with different Superscript are non-significant at P < 0.05. Values in [ ] parentheses are % change over saline control and values in [ ]% are change over PTZ treatment.

Table 2

| S.No | Brain area | SC | PTZ | EE + PTZ | nHE + PTZ | CE + PTZ | EAE + PTZ | nBE + PTZ | AE + PTZ | DZ + PTZ |
|------|------------|----|-----|----------|------------|----------|----------|----------|---------|---------|
| 1 CC | 4.869(a)   | 3.218(b) | 2.064(c) | 6.207(d) | 3.716(e) | 6.338(f) | 5.009(g) | 2.583(h) | 7.18(i) |
| 2 CB | 5.297(a)   | 5.401(b) | 2.747(c) | 3.492(d) | 2.483(e) | 5.477(f) | 5.603(g) | 6.397(h) | 0.705(i) |
| 3 PM | 5.074(a)   | 3.407(b) | 2.157(c) | 0.317(d) | 0.317(e) | 0.317(f) | 0.317(g) | 0.317(h) | 0.317(i) |
| 4 HC | 4.973(a)   | 3.017(b) | 2.135(c) | 6.437(d) | 4.497(e) | 5.313(f) | 5.997(g) | 2.993(h) | 6.935(i) |

All the values are Mean, ±SD of six individual observations. Values with same Superscript is significant at P < 0.05. Values with different Superscript are non-significant at P < 0.05. Values in [ ] parentheses are % change over saline control and values in [ ]% are change over PTZ treatment.

Table 3

| S.No | Brain area | SC | PTZ | EE + PTZ | nHE + PTZ | CE + PTZ | EAE + PTZ | nBE + PTZ | AE + PTZ | DZ + PTZ |
|------|------------|----|-----|----------|------------|----------|----------|----------|---------|---------|
| 1 CC | 5.424(a)   | 4.420(b) | 8.799(c) | 7.134(d) | 5.557(e) | 5.690(f) | 8.442(g) | 4.152(h) | 9.11(i) |
| 2 CB | 5.336(a)   | 3.656(b) | 7.051(c) | 6.297(d) | 6.708(e) | 7.316(f) | 8.327(g) | 8.558(h) | 8.465(i) |
| 3 PM | 7.795(a)   | 6.180(b) | 9.298(c) | 9.600(d) | 8.661(e) | 8.879(f) | 8.996(g) | 6.698(h) | 9.975(i) |
| 4 HC | 7.676(a)   | 6.176(b) | 9.524(c) | 8.792(d) | 8.998(e) | 9.298(f) | 9.759(g) | 5.614(h) | 9.656(i) |

All the values are Mean, ±SD of six individual observations. Values with same Superscript is significant at P < 0.05. Values with different Superscript are non-significant at P < 0.05. Values in [ ] parentheses are % change over saline control and values in [ ]% are change over PTZ treatment.
excitatory neurotransmission in CNS during epilepsy. Different extracts of *Bacopa monnieri* cause perceptible changes in the cholinergic system, at least as part of its antiepileptic effect. In the present study, the ACh content and AChE activities recorded changes that were maximal with nHE, EAE, nBE and CE. After the antiepileptic treatment with different BM extracts, the ACh content vis-à-vis Cholinesterase activities started returning to the control levels reaching more or less to the control levels, suggesting that selected BM extracts offer neuroprotection by ameliorating the cholinergic activity during induced epilepsy.

The work in this study has also been taken up with the aim of examining the changes in the enzymes concerned with energy metabolism and membrane transport functions, viz. Na\(^+\)/K\(^+\) -, Mg\(^2+\) - and Ca\(^2+\) -ATPase activities. The changes were recorded with different extracts of *Bacopa monnieri* enzymes following the administration of epileptic drug PTZ. Sodium Potassium ATPase and Calcium ATPase are membrane bound enzymes and play a pivotal role in the homeostasis of Na\(^+\), K\(^+\) and Ca\(^2+\) in the cells. Apart from these active transport mechanisms, ionic balance is also affected by the activities of sodium and potassium channels whose activity (open or closed condition) is voltage dependent. It has been reported that alteration in the activities of different ATPases during stress might have broader biological effects such as alteration in the permeability property of nerve membrane to Ca\(^2+\) ions, the blockage of the membrane to the passage of Na\(^+\) ions and inhibition of sodium-potassium pump. The activity levels of different ATPases were decreased in all the brain areas during PTZ-induced epilepsy. The declined activity of ATPases with PTZ administration is in agreement with earlier reports.\(^{35,40}\) Parallel to the Na\(^+\)/K\(^+\) - and Ca\(^2+\) -ATPases, the decreased activity of Ca\(^2+\) -ATPases suggests its involvement in Ca\(^2+\) -dependent quantal release of neurotransmitters with particular reference to cholinergic and adrenergic neurons.

Although the mechanism of inhibition of ATPase in PTZ-induced epilepsy is not clear, it is presumed that PTZ, the GABA antagonist, induces oxidative stress as evidenced by significant enhancement of lipid peroxidation in different regions of rat brain which might cause alterations in the membrane architecture and activity level of membrane bound enzymes including ATPases. In addition, it has also been reported that neurochemical alterations during PTZ-induced epilepsy might be implicated to the generation of free-radicals through altered antioxidant defense mechanisms.\(^{41}\) Hence,
membrane lipid peroxidation associated with an altered membrane fluidity, altered permeability to ions and changes in the activity of membrane bound enzymes have been implicated in the PTZ-induced epilepsy. Inhibition of the activities of all three ATPases, as observed in the present investigation, leads to uncontrolled dendritic discharges in Purkinje cells of rat cerebellum, and causes electrophysiologically recorded seizures. Emerging evidence suggest that certain epilepsies may be a family of channelopathies with defects involving mutations in the Na⁺/K⁺ or Ca²⁺ channels whose activities are related to their voltage dependent conditions or defects in the membrane-bound enzymes such as Na⁺/K⁺ ATPase and Ca²⁺ ATPase that regulate the transport of ions across the cell membrane. Defects in Na⁺ and K⁺ transport have also been implicated to the reduced clearance of extracellular K⁺ released from depolarized neurons during epilepsy. It has also been reported that the defect may be in the passive or active transport mechanisms where in Na⁺/K⁺ ATPase could be altered which has an indirect bearing on Ca²⁺ transport mechanism involving Ca²⁺ ATPase activity. Lowered enzyme activities of ATPases in epilepsy might be due to this defect apart from possible defect in cell membrane.

The increase in the activity levels of Na⁺/K⁺ ATPase and Ca²⁺ ATPase observed in the present investigation is similar to the results seen in the case of animal models also. Rapport et al. (1981) have found reduced activity of Na⁺/K⁺ ATPase in human and monkey epileptic brain. Trams and Lauter (1978) found a deficiency of ecto - Ca²⁺ ATPase in seizure prone mice. Indeed, various CNS disorders such as seizures, Parkinson, Huntington, and Alzheimer diseases have been associated with mitochondrial dysfunction, excitotoxicity, and generation of reactive oxygen species generation. Since the ionic balance in the neurons are important in the conduction of action potentials, the decrease in the activities of ATPases possibly alter the flux of ions thus alter the membrane permeability properties during induced epilepsy. All the three ATPases showed increased activities in all the regions of brain of epileptic rats after pre-treatment with different extracts of BM except AE. The present findings are in agreement with the observations of Oliveira et al. (2004). Our results indicate that GABAergic failure may underlie the currently observed inhibition of ATPase activity by PTZ, and that Bacopa monnieri extracts may act on the GABAergic system, since it also prevented the convulsions and inhibition of ATPase activity induced by PTZ. Our results also suggest that the neuroprotective effect of DZ, EE, nBE, nHE, EAE, and CE extracts against PTZ induced seizures. Several authors have shown that B. monniera was able to prevent lipid peroxidation in vitro and in vivo, and quench super oxide, hydroxyl and nitric oxide radicals effectively in vitro. It is widely accepted that neuronal damage can be significantly minimized by free radical scavengers. B. monniera showed significant antioxidant effect per se and in stressed animals. It has been shown that B. monniera protected morphine induced rat brain mitochondrial damage that could have favored the efficiency of ATP production. This energy-promoting action may be responsible for the improved mitochondrial function and maintenance of ATPases in the present study.

Although not related to the present studies, it has been shown that Curcumin plays neuroprotective role by elevating Na⁺/K⁺ ATPase activity in all the brain regions of rat. Similar elevation of ATPase activity levels have also been reported in brain microsomes of rats pre-treated with Curcumin. Studies have also shown that Bacoside A, an active factor from Bacopa monnieri, cause marked inhibition in lipid peroxidation, activation of the activities of ATPases, and also maintains ionic equilibrium. Similarly, Ginkgo biloba extract (ECG761) pre-treatment exhibited conspicuous neuroprotective effect by activating the activities of ATPases and inhibiting the lipid peroxidation that were altered during ischemia. The present findings in conjunction with the earlier reports suggest that the bioactive factors presented in selected extracts of BM exhibit neuroprotective and antioxidant effects by reversing the purinergic metabolism that has been inhibited during PTZ-induced epilepsy. These findings add to the growing list of channelopathies and suggest that drugs that directly or indirectly modulate the activities of the ATPases will be helpful in the treatment of seizure disorders.

5. Conclusion

The results obtained in the present investigation reveal that there is a significant positive regulation of all the selected neurochemical parameters during pre-treatment with Ethanol extract (EE), n-Hexane extract (nHE), Ethyl acetate extract (CE) and n-Butanol extract (nBE) in all the brain regions studied. These four extracts of Bacopa monnieri considerably increased the seizure threshold in the experimental model of generalized tonic-clonic seizures and elicit perceptible changes in different facets of neurotransmitter systems and the associated metabolic profiles, at least, as part of its antiepileptic effect. These extracts were found to have a challenging role in quenching the PTZ-induced abnormalities that occur in cholinergic system, and ATPases in different brain regions of rat. Hence, the information gained from the present study can be used for proposing a better pharmacological tool for the treatment of epilepsy and related neurological disorders. Thus, these four extracts may be beneficial in antiepileptic treatment or the bioactive compounds present in these extracts can be used in the formulation of herbal drugs which can be used in the treatment of epilepsy or to control the seizure generation. Since Bacopa monnieri exhibited anti-seizure activity as evidenced from the present investigation, it might be clinically useful in the control of human epilepsies.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgements

The authors are thankful to Department of Zoology, Sri Venkateswara University for providing lab facilities.

References

1. Khazipov R. GABAergic synchronization in epilepsy. Cold Spring Harb Perspect Med. 2016;6(2):227–244.
2. Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res. 2002;50:3–16.
3. Serra M, Dazzi L, Cagetti E, et al. Effect of Pentylenetetrazole-induced kindling on Acetylcholine release in the hippocampus of freely moving rats. J Neurochem. 1997;68:313–318.
4. Aronstam R, Kellogg C, Aboud L. Development of muscarinic cholinergic receptors in inbred strain of mice: identification of receptor heterogeneity and relation to audiogenic seizure susceptibility. Brain Res. 1979;162:231–241.
5. Elazar Z, Berchanski A. Excitatory amino acids modulate epileptogenesis in the brain stem. Neuroreport. 2000;11(8):1777–1780.
6. Curia G, Longo D, Biagini G, Jone RSG, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008;172(2):143–157.
7. Gendron FP, Benrezzak G, Krugh BW, Kong Q, Weissman CA, Beaudoin AR. Puine signaling and potential new therapeutic approach: possible outcomes of NPTDase inhibition. Curr Drug Targets. 2002;3:229–245.
8. Littleton JT, Bellen HJ. Synaptotagmin controls and modulates synaptic-vesicle fusion in a calcium-dependent way. Trends Neurosci. 1995;18:16–24.
9. Kodama T. Thermodynamic analysis of muscle ATPase mechanisms. Physiol Rev. 1985;65:467–551.
10. Krishnamoorthy E. Psychiatric issues in epilepsy. Curr Opin Neurol. 2001;14:217–224.
11. Lal S, Barai B. Phytochemical and pharmacological profile of Bacopa monnieri an ethnomedicinal plant. Memory. 2018;10(3):1001–1013.
12. Strough C, Lloyd J, Clarke J, Downey L, Hutchison WC, Rodgers T. The chronic
effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156:481–484.

13. Das A, Shanker G, Nath C, Pal R, Singh S, Singh KH. A Comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba. Anti-cholinesterase and cognitive enhancing activities. Pharmacol, Biochem Behav. 2002;73:893–900.

14. Sumathy T, Subramanian S, Govindasamy S. Protective role of Bacopa monniera on morphine induced hepatotoxicity in rats. Phytother Res. 2002;15:643–645.

15. Sairam K, Dorababu M, Goel RK, Bhattacharya SK. Antidepressant activity of Bacopa monniera in experimental models of depression in rats. Phytomedicine. 2002;9:207–211.

16. Pawar R, Gopalakrishnan C, Bhutani KN. Dammarane triterpene sapogenin from Bacopa monniera as the superoxide inhibitor in Polymorphonuclear cells. Plant Med. 2001;67:752–775.

17. Russo A, Channa S. Calcium antagonistic activity of Bacopa monniera. J Ethnopharmacol. 2003;73:1517–1526.

18. Sairam K, Rao CV, Babu MD, Goel RK. Prophylactic and curative effects of Bacopa monniera in gastric ulcer models. Phytomedicine. 2001;8:423–430.

19. Dar A, Channa S. Calcium antagonistic activity of Bacopa monniera on vascular and intestinal smooth muscles of rabbit and Guinea-pig. J Ethnopharmacol. 1999;66:167–174.

20. Phrompittayarat Watoo, Putalun W, Tanaka H, Jetiyanon K, Wittaya-areekul S. Anticonvulsant effect of Bacopa monniera in gastric ulcer models. Phytomedicine. 2001;8:423–430.

21. Ray SK, Poddar MK. Effect of pentylenetetrazol on carbaryl-induced changes in catecholamine-sensitive adenosine triphosphatase in mouse brain. Biochemical Pharmacol. 1972;11:253–259.

22. Miller FR, Stavraky GW, Woonton GA. Effects of eserine, acetylcholine and atropine on the electrocoercrogram. J Neurophysiol. 1940;3:131–138.

23. Komali E, Venkataramaiah C, Rajendra W. Anticonvulsant effect of Bacopa monnieri extracts on Catecholamine metabolism during PTZ-induced Epilepsy. J Neurochem. 2003;9(2):192.

24. Bhattacharya SK, Bhattacharya A, Kumar A. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14:174–179.

25. Ellman GL, Courtney KL, Andres VJ, Featherstone RM. A new and rapid colorimetric determination of inorganic phosphate in the presence of labile phosphate esters. Biochem Pharmacol. 1961;7:88–95.

26. Hestrin S. The reaction of Acetylcholine and other carboxylic acid derivatives with Hydroxylamine, and its analytical application. J Biol Chem. 1949;180:249.

27. Augustinsson KB. Assay methods for cholinesterases. In: Glick D, ed. Methods of Biochemical Analysis. vol. 5. New York: Interscience Publishers Inc.; 1957:1–63.

28. Desai A, Ho IK. Effect of acute and continuous morphine administration on catecholamine-sensitive adenosine tri phosphatephase in mouse brain. J Pharmacol Exp Therapeut. 1979;208:80–85.

29. Bhattacharya SK, Bhattacharya A. The determination of inorganic phosphate in the presence of labile phosphate esters. J Biol Chem. 1946;162:421–428.

30. Phillips TD, Hayes AW. Effects of patulin on ATPase in mouse. Toxicol Appl Pharmacol. 1977;42:175–188.

31. Tursi I, Economou C, Turski WA, Bortolotto ZA, Cavaleiro EA. Cholinergic mechanisms and epileptogenesis, the seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse. 1989;3:154–171.

32. Miller FR, Starvaky GW, Woonoton GA. Effects of eserine, acetylcholine and atropine on the electrocoercrogram. J Neurophysiol. 1940;3:131–138.

33. Farrandez HL, Hodges-Savola CA. Trophic regulation of Acetylcholinesterase isoenzymes in adult mammalian skeletal muscles. Neurochem Res. 1992;17:115–124.

34. Camarini R, Benedito MA. Chronic imipramine treatment-induced changes in acetylcholinesterase (EC3.1.1.7) activity in discrete rat brain regions. Braz J Med Biol Res. 1997;30:955–960.

35. Kishore M, Singh M. Effect of bacicides, alcoholic extract of Bacopa monniera Linn. (Brahmi), on experimental amnesia in mice. Indian J Exp Biol. 2005;43:640–645.

36. Bhattacharya SK, Bhattacharya A, Kumar A. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14:174–179.

37. Goldberg AM, Pollock J, Hartman ER, Craig CR. Alterations in cholinergic enzymes during the development of cobalt-induced epilepsy in the rat. Neuropharmacology. 1972;11:253–259.

38. Friedman A, Behrens CJ, Heinemann U. Cholinergic dysfunction in Temporal lobe epilepsy. Epilepsia. 2007;48(5):126–130.

39. Rapport RL, Harris AB, Lockhard JS, Clark AF. Na+ K⁺ -ATPase in serially excised segments of epileptic monkey cortex. Epilepsia. 1981;22:123–127.

40. Rosenblatt DE, Lauter CJ, Trams EG. Deficiency of a Ca²⁺-ATPase in brains of seizure prone mice. J Neurochem. 1976;27:1299–1304.

41. Siva Prasad K. Anticonvulsant Properties of Centella Asiatica against Pentylenetetrazol-Induced Epilepsy in Rats. Tirupati: Ph.D thesis submitted to Sri Venkateswara University; 2009.

42. Arundhati K, Mohan Das S, Padma T. Reduced activity of red cell Na⁺ K⁺ -ATPase and Ca²⁺-ATPase in patients with idiopathic generalized epilepsy. Int J Hum Genet. 2003;3:59–63.

43. Trams EG, Lauter CJ. On the sidedness of plasma membrane enzymes. Biochim Biophys Acta. 1974;345:180–197.

44. Cassarino DS, Bennett JP. An evaluation of the role of mitochondria in Neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev. 1999;29:1–25.

45. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P A sucessin transgenic mouse-A model of familial Parkinson's disease. Neurobiol Dis. 2005;18:492–498.

46. Oliveira MS, Furian AF, Royes FF, et al. Ascorbate modulates pentylenetetrazol-induced convulsions biphasically. Neuroscience. 2004;128:721–728.

47. Tripathi YB, Chaurasia S, Tripathi E, Upadyay A, Dubey GP. Bacopa monniera Linn. In mice. Neuromuscul Disord. 2009;19:107.

48. Trams EG, Lauter CJ. On the sidedness of plasma membrane enzymes. Biochim Biophys Acta. 1974;345:180–197.

49. Saiyed A, Channa S. Calcium antagonistic activity of Bacopa monniera on vascular and intestinal smooth muscles of rabbit and Guinea-pig. J Ethnopharmacol. 1999;66:167–174.

50. Phrompittayarat Watoo, Putalun W, Tanaka H, Jetiyanon K, Wittaya-areekul S, Ingkaninan K. Comparison of various extraction methods of Bacopa monnieri. Naresuan Univ J. 2007;15(1):29–34.

51. Ray SK, Poddar MK. Effect of pentylenetetrazol on carbaryl-induced changes in striatal catecholamines. Biochem Pharmacol. 1985;34:553–557.

52. Gupta M, Mazumder UK, Bhutani KN. Dammarane triterpene sapogenin from Bacopa monniera as the superoxide inhibitor in Polymorphonuclear cells. Plant Med. 2001;67:752–775.

53. Sairam K, Rao CV, Babu MD, Goel RK. Prophylactic and curative effects of Bacopa monniera in gastric ulcer models. Phytomedicine. 2001;8:423–430.

54. Dar A, Channa S. Calcium antagonistic activity of Bacopa monniera on vascular and intestinal smooth muscles of rabbit and Guinea-pig. J Ethnopharmacol. 1999;66:167–174.